Growth funding Myricx Bio has secured a substantial Series A funding round with notable investors (Sofinnova Partners, Novo Holdings, Abingworth, Brandon Capital, Eli Lilly, British Business Bank and Cancer Research Horizons) totaling around £90m (US$114m) in 2024, signaling strong traction and potential for partnership financing and grant-aligned collaborations.

Executive momentum Recent leadership and governance updates include the appointment of Mohit Rawat as CEO and David Ellis as VP Regulatory Affairs, indicating a drive toward clinic readiness and regulatory strategy, which opens doors for early collaboration on translational programs and regulatory consulting opportunities.

Clinical pathway Focused on a novel class of NMT inhibitor–based payloads for antibody drug conjugates in cancer, presenting a differentiated modality with potential appeal to large pharma and biotech partners seeking innovative ADC platforms to expand their oncology pipelines.

Strategic partnerships High-profile investors and a UK-based tech-enabled biotech profile suggest receptivity to co-development, licensing, or research collaboration deals, especially with companies seeking access to unique payload technologies and ADC capabilities.

Market readiness With a small yet growing team (11-50 employees) and near-clinic development trajectory, there is opportunity for early engagement around CRO/CMO support, regulatory affairs services, and scalable manufacturing partnerships to accelerate preclinical-to-clinic milestones.